Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2023-03-14 00:00:00 ET · period of report 2023-03-13 · accession 0001062993-23-006867 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-03-14 | 2023-03-13 | ENTA | Luly Jay R. | Pres, CEO, Dir | S - Sale+OE | $45.16 | -27.9K | 837.0K | -3% | -$1.26M |
| D | 2023-03-14 | 2023-03-13 | ENTA | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $14.00 | +27.9K | 847.7K | +3% | +$390.8K |
| D | 2023-03-14 | 2023-03-13 | ENTA | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $0.00 | -27.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-13 | S | D | 15,649 | $45.31 | 821,376 | D | — | — | (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. |
| 2 | Common | Common Stock | 2023-03-13 | M | A | 27,912 | $14.00 | 847,722 | D | — | — | |
| 3 | Common | Common Stock | 2023-03-13 | S | D | 1,566 | $46.13 | 819,810 | D | — | — | (F4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.54, inclusive. |
| 4 | Common | Common Stock | 2023-03-13 | S | D | 10,697 | $44.81 | 837,025 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.39 to $44.99, inclusive. |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-03-13 | M | D | 27,912 | $0.00 | 0 | D | $14.00 · — to 2023-03-21 | 27,912 Common Stock | (F5) On March 21, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, half of which became exercisable upon the achievement of several clinical milestones during the four-year performance period after the date of grant. |